FDA-approved quinazolines constitute a promising group of drugs against different types of tumors in cancer and mechanistically inhibit the protein kinase of the epidermal growth factor receptor (EGFR), inactivating the anti-apoptotic pathway [40,41,42,43]. The gene discussed is EGFR; the disease is cancer.